glp-1 drug novo nordisk asks FDA to prevent compounders from making knockoffs GLP-1 Drug Fails to Quell
Description
Semaglutide at the 2.4 mg dose (the maximum approved for weight management) produces roughly 15-17% body weight reduction in clinical trials
Lancet Gastroenterol Hepatol 2023;8:17991.ArticlePubMed 82
This is sure to accelerate the adoption of this medication
Ozempic (semaglutide) and Saxenda (liraglutide) vigilance required due to potentially harmful falsified products
Tirzepatide continues to broaden its label
doi: 10.3892/etm.2016.3742 86 PatzeltCSchugG
